CMET-22. PCV VS TEMOZOLOMIDE CHEMOTHERAPY FOR PATIENTS WITH LGG: A SYSTEMATIC REVIEW AND META-ANALYSIS

Abstract

BACKGROUND: Low-grade glioma (LGG) encompasses a heterogeneous group of tumors that is clinically, histologically and molecularly diverse. Treatment decisions are directed toward improving upon natural history, while limiting treatment-associated toxic effects. Recent evidence has documented a utility for adjuvant chemotherapy in the management of LGG. OBJECTIVES: Determine the comparative utility of temozolomide (TMZ) and procarbazine/lomustine/vincristine (PCV) for patients with LGG, particularly in the context of molecular subtype. METHODS: A literature review was conducted to identify studies reporting patient response to PCV, TMZ, or a combination of chemotherapy and radiation therapy (RT). Eligibility criteria included LGG subtype, 18